GLEM LIN MXR 5MG 2.5 1000MG TAB 14
Glem-Lin MXR 5/2.5/1000 mg Tablets – Triple Action Diabetes Control | 14’s Pack
📄 Product Description
Glem-Lin MXR 5 / 2.5 / 1000 mg is an advanced oral anti-diabetic medication in a triple-action extended-release (MXR) formulation, combining Empagliflozin, Linagliptin, and Metformin HCl to help manage type 2 diabetes mellitus more effectively. This once-daily tablet is designed to control high blood sugar levels through multiple mechanisms — improving insulin secretion, reducing glucose production, and increasing glucose elimination — all in one convenient dose.
🧪 Active Ingredients (per Tablet)
✔ Empagliflozin 5 mg – SGLT2 inhibitor helps remove excess glucose via urine.
✔ Linagliptin 2.5 mg – DPP-4 inhibitor increases insulin release and reduces glucagon.
✔ Metformin HCl 1000 mg (Extended-Release) – Biguanide that lowers glucose production in the liver and improves insulin sensitivity.
🩺 Uses
• Helps control high blood sugar (hyperglycemia) in adults with type 2 diabetes mellitus.
• Used when diet, exercise, or single drug therapies alone are insufficient.
• Aims to reduce HbA1c levels and stabilize daily glucose fluctuations.
• May support weight management and reduce cardiovascular risks as part of a comprehensive diabetes plan.
🌟 Benefits
✨ Triple-Mechanism Action – Tackles glucose control through kidney, pancreatic and liver pathways.
✨ Extended-Release Form – Provides steady glucose control throughout the day.
✨ Once-Daily Dosing – Convenient for long-term adherence.
✨ Comprehensive Therapy – Ideal for patients not adequately controlled with dual therapy.
⚠️ Side Effects & Precautions
Possible side effects include:
• Nausea, diarrhea, abdominal discomfort
• Urinary tract or genital infections (linked to Empagliflozin)
• Hypoglycemia (low blood sugar) when used with insulin or secretagogues
• Very rare but serious risks: lactic acidosis (associated with Metformin) and allergic reactions.
⚠ Not for use in type 1 diabetes or diabetic ketoacidosis and requires renal function monitoring. Always consult your healthcare provider before starting or adjusting doses.
🧠 How It Works
This triple combination offers a synergistic approach:
• Empagliflozin helps the kidneys excrete glucose.
• Linagliptin enhances insulin release and reduces glucagon.
• Metformin decreases glucose production in the liver and increases insulin sensitivity. Together, they help keep blood sugar within target ranges.
🏭 Manufacturer / Brand
Brand: Glem-Lin MXR
Manufacturer: Nabiqasim Pharmaceutical – a pharmaceutical company producing combination diabetes medications.